NICE rejects 2 drug combos for a certain type of breast cancer:

12/14/2010 | Google

Draft guidance issued by the U.K.'s National Institute for Health and Clinical Excellence does not endorse the use of GlaxoSmithKline's Tyverb or Roche Holding's Herceptin in addition to an aromatase inhibitor for women with hormone-receptor and HER2-positive breast cancer. "The evidence suggests that these drug combinations do not offer enough additional value to patients over and above currently available treatment to justify the high cost that the [National Health Service] would have to pay for them," NICE CEO Andrew Dillon said.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD